DAYTON, Ohio--(BUSINESS WIRE)--ClearRead CT results have been published in a study titled "Computer-Aided Detection of Lung Nodules on CT with a Computerized Pulmonary Vessel Suppressed Function" in the prestigious American Journal of Roentgenology.
ClearRead CT is comprised of two powerful tools, ClearRead CT | Vessel Suppress and ClearRead CT | Detect. Deep learning enables the vessel suppression technology to assist both machine and humans in the detection and characterization of all primary nodule types, allowing for previously unattained nodule detection performance.
The study documents the results of a multi-reader, multi-case, blinded reader study that shows the benefits of ClearRead CT both in terms of improved reading efficiency and reading accuracy.
ClearRead CT is the first FDA cleared concurrent read device incorporating a novel vessel suppression technology based on deep learning that aids in the detection and characterization of solid, part-solid and ground glass nodules.
Riverain Technologies is a leader in the commercialization of Clinical AI, offering five FDA cleared products that incorporate state-of-the-art machine learning technologies.
To learn more about Riverain Technologies and ClearRead CT, please visit our website, www.riveraintech.com.
Riverain Technologies is a clinical AI software innovator that develops solutions to aid clinicians in the early detection of disease. For more information visit: http://www.riveraintech.com.